Psyence Biomedical Ltd. reported a convertible debt financing agreement totaling up to $12.5 million, with $3.125 million already issued on January 15, 2024, and an additional $312,500 on May 31, 2024, with obligations guaranteed by certain company assets. This financing is subject to various conditions, including compliance with existing agreements, to avoid significant penalties.